Cary, N.C. , June 8, 2026 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by AbbVie as the exclusive specialty pharmacy provider for DECNUPAZ™ (pivekimab sunirine-pvzy), an intravenous therapy approved for the treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
BPDCN is an ultra-rare and aggressive hematologic malignancy. The disease commonly presents with skin lesions and frequently spreads to the bone marrow, central nervous system and lymph nodes. BPDCN is considered difficult to diagnose and is more common in older adults, occurring more frequently in men than women. (Source: National Cancer Institute and Dana-Farber Cancer Institute)
First-line therapy often involves chemotherapy, and eligible patients may proceed to stem cell transplant. However, treatment options remain limited – particularly for individuals whose disease has relapsed or become refractory. (Source: Dana-Farber Cancer Institute and HealthTree Foundation)
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For the full prescribing information for DECNUPAZ™ (pivekimab sunirine-pvzy), please visit https://www.rxabbvie.com/pdf/decnupaz.pdf.